Home
About Us
Company Profile
Enterprise culture
Honor
History
Industrial park project
Multimedia Area
Products
Featured Items
Chemiluminescence
Quantum dot platform
Biochemical series
Home self-test
Biomaterial/scientific research
News
Company News
Industry News
Recruitment
Contact Us
Language
中文
English
日本語
한국어
Quick Detection · Joint Indicator · Quantitative Analysis
Quick Detection · Dual Union indicator · Quantitative Analysis
The fluorescent quantity platform has high sensitivity, stable performance, and true and reliable signals.
Convenience, security, practical, accuracy · intelligence
Product display
Diabetic kidney disease non-invasive detection system
Product status: international initiative, invention patent product(ZL 2017 1 0507989.9) Product status: 2021 China IVD Gold Award project, the sixth batch of suitable technology promotion projects in Anhui Province Product value: used for in vitro detection of early diagnostic indicators of diabetic nephropathy in human urine Product categories: urine testing, second-class products, dry biochemistry + immunity Product features: multi-channel composite detection, selected index combination, urinary microalbumin, urinary haptoglobin (exist in the blood of early diabetic patients, can occur before microalbumin, so the sensitivity is higher, and it is the latest Early diagnostic index of diabetic nephropathy), urine creatinine (as an internal standard, to standardize the detection value. Non-destructive test method, random urine independent test, dry reagent, superior than wet test, easy to carry, store and transport, traits The stability time is relatively longer than that of wet reagents. A series of testing products are developed according to different needs, and a two-level testing system is gradually formed. On the one hand, urine testing equipment is equipped in hospitals and physical examination centers to carry out precise quantitative testing; on the other hand, patients can be at home. Self-inspection, and can take photos and upload test results through mobile communication devices such as mobile phones, and the server will analyze and give feedback, and give professional suggestions or opinions in time.
Prevention of miscarriage and premature birth monitoring system
Product status: domestic exclusive product, invention patent(ZL 2019 1 0493157.5) Product status: the fifth batch of suitable technology promotion projects in the country and Anhui Province Product value: To specifically diagnose the markers of premature rupture of membranes and premature delivery in vaginal secretions of pregnant women, and provide clinical basis for diagnosing rupture of membranes and predicting premature delivery Product categories: Prenatal and postnatal care, immunodiagnosis Product features: rapid detection, dual indicators, quantitative analysis Market demand: Preterm birth is one of the main causes of neonatal morbidity and death. Accurately predicting the occurrence of premature birth is the key to reducing the incidence and mortality of premature birth. Premature rupture of membranes is one of the main causes of premature birth.
Urine iodine detection system
Product status: domestic leading, invention patent(ZL 2016 1 1262242.3) Product status: Urine iodine detection kit (oxidative chromogenic method), urine iodine quantitative analyzer obtained the "People's Republic of China Medical Device Registration Certificate (in vitro diagnostic reagents) approved by Anhui Food and Drug Administration in July 2016 )" (Registration Certificate No.: Wanji Zhuzhun 20162400209) and "Medical Device Registration Certificate of the People's Republic of China" (Registration Certificate No.: Wanji Zhuzhun 20162400208), which have been sold to the market. The second-generation fully automatic machine is under development and will be launched by the end of 2023. Product value: Quantitatively detect the iodine content of human urine in vitro, which is used to evaluate the iodine nutritional status of the population, which belongs to the intelligence element. Product category: urine testing, second-class products Market demand: pregnant women, children, endocrine, physical examination center
Gastric function screening series
Product status: blue ocean product Product Status: Approved for listing in September 2022. Product value: PGⅠ/Ⅱ\G17 serological joint detection, the level changes of each index reflect the gastric mucosal atrophy site, and effectively distinguish the types of gastric atrophy. Product categories: gastric function screening, immunodiagnosis Product features: rapid detection, joint indicators, quantitative analysis Market demand: Smoking, heavy drinking, staying up late, irregular diet, chronic atrophic gastritis, gastric ulcer, gastric polyps and other gastric diseases in the past, HP infection and other people are the screening objects. In 2017, the Chinese Anti-Cancer Association promulgated the "Expert Consensus Opinions on Early Gastric Cancer Screening Process in China (Draft)", recommending regular gastric cancer screening for people over 40 years old. Early detection can more effectively control or cure gastric cancer.
Three core technology platforms
IVD (In Vitro Diagnostic Reagents) Industrialization Platform
See more →
Medical Device Manufacturing Platform
Biological raw materials/scientific research achievements transformation platform
Follow us to keep abreast of the company's news
2024-01-22
Serving the big health industry, leapfrogging development of industry, academia and research - Anhui Huibang Biotech bloomed at the Anhui Traditional Chinese Medicine Academic Annual Conference
2023-08-07
Urine and nephropathy and defense -Dialogue column of the Diabetes Branch of the Chinese Medical Association
On August 4, 2023, the Chinese Medical Association Diabetes Branch 2023 Education Management Academic Conference was grandly held at Fengda International Hotel, Hefei City, Anhui Province.
2023-06-29
Good news! Huibang Biotechnology won the second prize of Science and Technology Progress Award of the Ministry of Education!
Recently, the Ministry of Education issued a certificate for the Outstanding Achievement Award (Science and Technology) of Scientific Research in Institutions of Higher Learning. Anhui Huibang Bioengineering Co., Ltd. jointly with the Chinese Academy of Sciences and Capital Medical University declared the project: "Research and Application of Molecular Targets for Diabetes" won the second prize of Science and Technology Progress Award of the Ministry of Education.
86-0551-65732099
Mailbox:3039898136@qq.comTelephone:86-0551-65732099Address: No.18, Diving East Road, High-tech Zone, Hefei City, Anhui Province
Focus on us
Copyright ©Huibang Biological Powered by: 300.cn Hefei
Business License SEO